Citius Oncology Inc (CTOR)

概要ニュース株価時系列ディスカッション予測

Relative Volume:

ネットキャッシュフロー:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1136)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

CTOR's Discussions on Twitter

CTOR を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
CTOR Citius Oncology Inc	1.2565	98.37M	0	0	0	0.00
ZTS Zoetis Inc	124.75	53.87B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.76	45.71B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.875	43.73B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	29.95	34.49B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	508.06	22.00B	3.08B	1.24B	1.07B	25.61

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2025-09-23	アップグレード	Maxim Group	Hold → Buy
2024-11-27	開始されました	Maxim Group	Buy

Citius Oncology Inc (CTOR) 最新ニュース

Citius Oncology Inc (CTOR) 財務データ

Citius Oncology Inc (CTOR) の財務データはありません。詳細については、他の銘柄を確認してください。

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR を他の銘柄と比較する

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc (CTOR) 最新ニュース

Is Citius Oncology Inc a good long term investmentCup and Handle Formations & Get Trading Help From Experienced Users - earlytimes.in

Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - MSN

Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria

Citius Oncology Raises $18M Through Direct Offering - TipRanks

Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus

Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Fidelity

Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat

Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada

Citius Oncology, Inc. announced that it has received $16.6 million in funding - marketscreener.com

Citius Oncology (NASDAQ: CTOR) raises $1.4M, adds large warrant package - Stock Titan

Citius Oncology added to the Russell Microcap Index - MSN

Citius Oncology shares sink after announcing $18M fundraising deal - MSN

Citius Oncology raises $18 million to support cancer therapy launch - Investing.com

Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com Nigeria

Citius Oncology stock tumbles after $18M capital raise - Investing.com

Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com

Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com

What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in

Citius Oncology Launches Lymphir In US For Skin Cancer - MSN

Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria

Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve

Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com India

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus

Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com

Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView — Track All Markets

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times

What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser

Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ

Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment - MSN

Citius Oncology enters distribution services agreement with Cardinal Health - MSN

Does Citius Oncology Inc (CTOR) offer a good opportunity for investors? - Setenews

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - marketscreener.com

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga

Citius launches Lymphir in USA for relapsed or refractory CTCL - The Pharma Letter

Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq

Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN

Will Citius Oncology Inc. stock continue upward momentumJuly 2025 Market Mood & Target Return Focused Picks - Newser

Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan

How Citius Oncology Inc. stock performs in weak economyWeekly Earnings Recap & Low Risk High Reward Ideas - Newser

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma - TipRanks

Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL - TradingView — Track All Markets

Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com

Citius Oncology announces U.S. commercial launch of Lymphir for cutaneous T-cell lymphoma - marketscreener.com

Citius Oncology stock soars after commercial launch of LYMPHIR therapy By Investing.com - Investing.com South Africa

Citius Oncology Inc (CTOR) 財務データ

収益

当期純利益

現金流量

EPS

CTORに似た銘柄